| 1. |
Wakizono, Takahiro
Nakashima, Hideyuki
Yasui, Tetsuro
Noda, Teppei
Aoyagi, Kei
Okada, Kanako
Yamada, Yasuhiro
Nakagawa, Takashi
Nakashima, Kinichi, Growth factors with valproic acid restore injury-impaired hearing by promoting neuronal regeneration, JCI insight, 10.1172/jci.insight.139171, 10.1172/jci.insight.139171, 2021.11. |
| 2. |
Teppei Noda, Noritaka Komune, Ryuji Yasumatsu, Nana Akagi Tsuchihashi, Akihiro Tamae, Nozomu Matsumoto, Kuniaki Sato, Ryutaro Uchi, Kensuke Koike, Takahiro Wakasaki, Risa Tanaka, Takashi Nakagawa, Therapeutic effect of Nivolumab for advanced / recurrent temporal bone squamous cell carcinoma, Auris Nasus Larynx, Volume 47, Issue 5, October 2020, Pages 864-869
, 2020.10, Objective: The immune checkpoint inhibitor nivolumab was approved for the treatment of platinum-refractory head and neck squamous cell carcinoma (SCC), expanding the treatment options for recurrent or advanced head and neck SCC. However, since temporal bone squamous cell carcinoma (TB-SCC) is very rare cancer, the effectiveness of Nivolumab remains unclear. We investigated the effects of nivolumab for TB-SCC.
Method: Chart information was collected for all patients who underwent the first administration of Nivolumab for recurrent or residual TB-SCC in our hospital between September 2017 and December 2019. Tumor staging followed the modified Pittsburgh classification. Changes in the tumor burden and survival outcome were examined.
Results: We examined 9 patients with recurrent or residual TB-SCC who started administration of Nivolumab. In these cases, recurrent or residual SCC was observed after chemotherapy and/or chemoradiotherapy including platinum. The duration of Nivolumab was 2-54 weeks (median 20.0 weeks). The evaluation of the therapeutic effect according to the RECIST method showed partial response in 1 cases, stable disease in 2 cases, progressive disease in 4 cases, and size unevaluated in 2 case. Although the number of cases was small, comparing with 5 cases without Nivolumab, these cases showed longer overall survival (1-year OS 33.3% vs 20.0%).
Conclusion: We used Nivolumab as palliative chemotherapy in 9 patients with recurrent/residual TB-SCC, and we were able to obtain a certain therapeutic effect on TB-SCC as well as other head and neck SCC.
. |
| 3. |
Teppei Noda, Steven J. Meas, Jumpei Nogami, Yutaka Amemiya, Ryutaro Uchi, Yasuyuki Ohkawa, Koji Nishimura, Alain Dabdoub, Direct Reprogramming of Spiral Ganglion Non-neuronal Cells into Neurons: Toward Ameliorating Sensorineural Hearing Loss by Gene Therapy, FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 10.3389/fcell.2018.00016, 6, online, 2018.02. |
